Effect of the Amino Acid L-arginine on Perioperative Cardio-vascular Risk in Non-selected Patients

• difference in incidence of the combined end-point of death of any cause [ Time Frame: period of 30 days after surgery ] [ Designated as safety issue: No ]
  the difference in incidence of the combined end-point of death of any cause, acute myocardial infarction or acute coronary syndrome, decompensated heart failure, cardiac arrest or resuscitation, and cerebral or pulmonary embolism between L-arginine and placebo.
  
  

• difference in incidence between L-arginine and placebo (subgroup with ADMA) [ Time Frame: period of 30 days after surgery ] [ Designated as safety issue: No ]
  difference in incidence between L-arginine and placebo for the subgroups with ADMA below and above the median concentration
  
  
• difference in incidence between beta-blocker or no beta-blocker treatment [ Time Frame: period of 30 days after surgery ] [ Designated as safety issue: No ]
  the difference in incidence of the combined primary end-point between patients on beta-blocker treatment or not on beta-blocker treatment
  
  
• difference in incidence between statin treatment or no statine treatment [ Time Frame: period of 30 days after surgery ] [ Designated as safety issue: No ]
  the difference in incidence of the combined primary end-point between patients on statin treatment or not on statin treatment
  
  
• difference in incidence between L-arginine and placebo (ASA class) [ Time Frame: period of 30 days after surgery ] [ Designated as safety issue: No ]
  -the difference in incidence of the combined primary end-point between L-arginine and placebo for each of the ASA classes II to IV
  
  

Patients will be recruited for this study from the participating Departments. In a previous study (protocol no. UKE-KP 2002/006) we investigated the predictive role of ADMA (asymmetric dimethylarginine) for peri-operative complications in unselected patients undergoing major surgery. The major result of that study was that patients with pre-operative ADMA plasma level within the highest quartile of the distribution had a significantly elevated risk of experiencing a serious peri-operative complication within a period of 30 days after the surgical intervention. These data have been published [Maas et al. 2007]. As ADMA competitively displaces L-arginine from the enzyme, NO synthase, it is expected that the adverse cardiovascular effects of high ADMA levels can be antagonized by supplemental L-arginine. Therefore, the present study was designed to specifically address the question whether dietary supplementation with L-arginine before the surgery, aiming at replenishing the body`s L-arginine stores, may help to reduce the peri- operative complication rate. Another aim is to assess whether this occurs in all patients or specifically in the subgroup with elevated baseline ADMA levels.

Study participants will be recruited from patients who routinely visit the outpatient clinic at the participating Departments of Anesthesiology and Intensive Care in advance of their planned surgical intervention. Patients usually visit the clinic between five working days in advance of the scheduled time of surgery, or they are admitted to in-patient treatment one or two days before the surgery. They will be informed about the scope and aim of the study, and after having given their informed consent, patients will receive L-arginine dietary supplements or corresponding placebo according to randomisation plan for the time until surgery. The last dosage of the L-arginine supplements will be taken in the morning of the surgery, dissolved in a glass of tap water that patients ware required to drink with premedication for anesthesia. Blood samples to measure plasma L-arginine and ADMA levels will be taken at the time of inclusion, in the morning before scheduled surgery, and on days 1 and 3 after the surgery and will together with additional safety parameter not exceed 80ml. No administration of study product will occur after surgery.

After surgery having taken place, patients will be monitored daily for as long as they remain being treated as in-patients, and all clinical events, changes in laboratory parameters, and apparatively performed clinical tests as scheduled according to clinical routine will be documented. No additional clinical treating will be performed on study participants, except the blood samples that will be taken as described above. After discharge, patients will be followed-up telephonically, for the last time at 30 days after the date of surgery. All clinical events occurring in this period will be recorded. In addition, changes in laboratory values, ECG recordings, and other apparative diagnostic measures will be checked for possible complications, and also be recorded.